Dyne Therapeutics Announces First Patient Dosed in Phase I/II DELIVER Clinical Trial of DYNE-251 for the Treatment of Duchenne Muscular Dystrophy

Dyne Therapeutics, Inc. announced that the first patient has been dosed in its Phase I/II clinical trial, DELIVER, evaluating DYNE-251 for the treatment of Duchenne muscular dystrophy mutations amenable to exon 51 skipping.
[Dyne Therapeutics, Inc.]
Press Release

Stay up-to-date with your field!

Subscribe for free weekly science newsletters.

Related News